WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 10 fonti

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

Raccontata dabiopharmadive.comstatnews.comendpoints.newseconomictimes.indiatimes.commorningstar.comindependent.co.ukmedpagetoday.comadnkronos.commedicalxpress.comgizmodo.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo1 mesi fa

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

originale

Timeline cronologica

  1. giovedì 28 maggio 2026·biopharmadive.com

    GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

    The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.

  2. giovedì 28 maggio 2026·statnews.com

    Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show

    An experimental GSK drug helped 1 in 5 patients with chronic hepatitis B achieve what's known as a functional cure, vastly outpacing current treatments.

morningstar.com
1 mesi fa

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to…

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Leggi questa versione → originale
economictimes.indiatimes.com1 mesi fa

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential…

Leggi questa versione → originale
gizmodo.com1 mesi fa

Experimental Drug May Offer a 'Functional Cure' for Some People with Chronic Hepatitis B

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all treatment.

Leggi questa versione → originale
medpagetoday.com1 mesi fa

Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials

Findings 'will change the landscape' of treatment, researcher says

Leggi questa versione → originale
endpoints.news1 mesi fa

GSK's functional cure data for hepatitis B drug are a major leap over standard of care

GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four markets including the US.

Leggi questa versione → originale
  • giovedì 28 maggio 2026·endpoints.news

    GSK's functional cure data for hepatitis B drug are a major leap over standard of care

    GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews…

  • giovedì 28 maggio 2026·economictimes.indiatimes.com

    GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

    GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of…

  • giovedì 28 maggio 2026·morningstar.com

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic…

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

  • giovedì 28 maggio 2026·independent.co.uk

    FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

    New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

  • giovedì 28 maggio 2026·medpagetoday.com

    Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials

    Findings 'will change the landscape' of treatment, researcher says

  • giovedì 28 maggio 2026·adnkronos.com

    Epatite B cronica, Gsk: "Con bepirovirsen tassi guarigione funzionale significativi"

    I risultati dei due studi di Fase III, B-Well 1 e B-Well 2, sono stati pubblicati simultaneamente sul 'New England Journal of Medicin'e e presentati al congresso dell’Associazione…

  • venerdì 29 maggio 2026·medicalxpress.com

    One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen

    In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well…

  • venerdì 29 maggio 2026·gizmodo.com

    Experimental Drug May Offer a 'Functional Cure' for Some People with Chronic Hepatitis B

    Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all treatment.